It all comes to the results of the GMP, if it is a great success then it opens all doors for studies not cancer related..
Non dilutive funding was mentioned many times by the Dr, the sporadic event kept them at bay, if a successful GMP will they return? Dx3 does not need ph 1 trials for people to start their own research but confirmation of our product can be made at scale is a must
Ann: Presentation to highlight broader potential of Deoxymabs, page-46
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $5.35K | 700.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 8854419 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 3165475 | 3 |
View Market Depth
| Last trade - 11.38am 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.7¢ | 0.7¢ | 0.7¢ | 496000 | ||
| Last updated 15.57pm 03/06/2024 ? | |||||
| PAB (ASX) Chart |